Skip to main content
. Author manuscript; available in PMC: 2013 Nov 11.
Published in final edited form as: Leukemia. 2012 Jul 13;27(1):10.1038/leu.2012.191. doi: 10.1038/leu.2012.191

Figure 5.

Figure 5

FLT3/ITD Y842C confers resistance in vivo, (a) BaF3 FLT3/ITD Y842C luc + cells were transplanted via tail vein in syngeneic Balb/c mice on day 0. Bioluminescence was monitored by peritoneal injection of luciferin on day 3 to monitor engraftment. Treatment with sorafenib (20 mg/kg, once daily), lestaurtinib (20 mg/kg, twice daily) or lestaurtinib vehicle control began on day 3 and continued until day 8 to assess FLT3 TKI activity, (b) The treatments described in (a) were continued until day 15 when mice in the control group became sick at which point spleen weights were measured in all groups. Values expressed are the means ± s.e.m.